The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Head and Neck Cancer
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1465038
The efficiency of Liposomal paclitaxel versus docetaxel in neoadjuvant chemotherapy with TPF regimen for locally advanced nasopharyngeal carcinoma: a retrospective study
Provisionally accepted- china,xiangxi, Jishou, China
Purpose This retrospective study aimed to explore the efficiency and untoward reaction of liposomal paclitaxel versus docetaxel for locally advanced nasopharyngeal carcinoma (NPC).Methods This retrospective study included 115 patients diagnosed with nasopharyngeal carcinoma (NPC) at our hospital between January 2018 and December 2021. Patients were stratified into two groups based on their treatment with either liposomal paclitaxel (n = 71) or docetaxel (n = 44) as part of the neoadjuvant chemotherapy regimen. Objective response rate (ORR), progression-free survival (PFS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were compared between the two groups.Results: ORR was significantly improved in the liposomal paclitaxel group than in the docetaxel group (62.0% versus 40.9%, P = 0.028). The 3-year PFS (PFS: 84.4% versus 77.5%, P = 0.303), LRFS (95.8% versus 94.4%, P = 0.810), DMFS (87.2% versus 83.0%, P = 0.443), and OS (90.7% versus 88.8%, P = 0.306) revealed no significance. The neutrophil-to-lymphocyte ratio (hazard ratio [HR]: 3.510; P = 0.039) and distant metastasis (HR: 4.384; P = 0.035) were regarded as the risk factors using multivariate regression analysis. Moreover, the incidence of leukopenia at grades 1-2 in the liposomal paclitaxel group was significantly lower than in the docetaxel group (28.1% versus 79.5%, P < 0.05).Conclusions Liposomal paclitaxel had better efficacy in terms of short-term effects and lower incidence of leukopenia at grades 1-2 compared with the docetaxel group.
Keywords: nasopharyngeal carcinoma, Neoadjuvant chemotherapy, Paclitaxel liposomes, DOCETAXEL, TPF regimen
Received: 15 Jul 2024; Accepted: 23 Sep 2024.
Copyright: © 2024 Yang, Zuo, Liu, Wu, Chen, Xiong, Jia and Xiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Quan Zuo, china,xiangxi, Jishou, China
Rong Liu, china,xiangxi, Jishou, China
Hui Wu, china,xiangxi, Jishou, China
Jia Chen, china,xiangxi, Jishou, China
Li Xiong, china,xiangxi, Jishou, China
Jieqi Jia, china,xiangxi, Jishou, China
Zhibi Xiang, china,xiangxi, Jishou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.